AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7725889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam hydrochloride (10 mg) in group B
Number of subjects: 90
Study 7725889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam hydrochloride (20 mg) in group C
Number of subjects: 90
Study 7725889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam hydrochloride in group B
Number of subjects: 90
Study 1904749 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen 200 mg
Number of subjects: 4
Study 1904749 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen 400 mg
Number of subjects: 4
Study 1904749 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen 800 mg
Number of subjects: 4
Study 1904749 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen 1200 mg
Number of subjects: 4
Study 1904749 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen (all doses)
Number of subjects: 4
Study 6100880 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 20 mg once-a-day
Number of subjects: 100
Study 6100880 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 31660693 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA anodal tDCS over left DLPFC (20 min)
Number of subjects: 36
Study 31660693 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 36
Study 29848108 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 915
Study 29848108 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 915
Study 29848108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 915
Study 27473924 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexia Reading Core5 intervention (n=49)
Number of subjects: 98
Study 27473924 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (n=49)
Number of subjects: 98
Study 24170766 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour suspension of basal insulin
Number of subjects: 17
Study 24170766 — intervention group
Group type: COMPARATOR
Intervention: Control nights (usual basal rates continued)
Number of subjects: 17
Study 22988681 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma (glutaraldehyde‐based desensitizing system)
Number of subjects: 22
Study 22988681 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 22
Study 20647511 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex Lite dressings
Number of subjects: 28
Study 20647511 — intervention group
Group type: COMPARATOR
Intervention: Standard aqueous cream
Number of subjects: 28
Study 20647511 — intervention group
Group type: EXPERIMENTAL
Intervention: TLD measurements
Number of subjects: 28
Study 20952606 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flexion posterior-stabilized rotating-platform mobile-bearing prosthesis
Number of subjects: 170
Study 20952606 — intervention group
Group type: COMPARATOR
Intervention: Standard posterior-stabilized rotating-platform mobile-bearing prosthesis
Number of subjects: 170
Study 16091060 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily for 52 weeks
Number of subjects: 31
Study 16091060 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 52 weeks
Number of subjects: 31
Study 12359996 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced warm air
Number of subjects: 60
Study 12359996 — intervention group
Group type: EXPERIMENTAL
Intervention: Rewarming protocol for hypothermic patients
Number of subjects: 60
Study 9495581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg i.v. twice a day for five days
Number of subjects: 194
Study 9495581 — intervention group
Group type: COMPARATOR
Intervention: i.v. placebo
Number of subjects: 194
Study 7803739 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg of protamine (Group I)
Number of subjects: 45
Study 7803739 — intervention group
Group type: EXPERIMENTAL
Intervention: HDRC with correction factor 1.3 (Group II)
Number of subjects: 45
Study 7803739 — intervention group
Group type: EXPERIMENTAL
Intervention: HDRC with correction factor 1.0 (Group III)
Number of subjects: 45
Study 7803739 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 45
Study 29505145 — intervention group
Group type: EXPERIMENTAL
Intervention: 500,000 IU D3
Number of subjects: 30
Study 29505145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29505145 — intervention group
Group type: EXPERIMENTAL
Intervention: 250,000 IU D3
Number of subjects: 30
Study 27488326 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (ST)
Number of subjects: 68
Study 27488326 — intervention group
Group type: COMPARATOR
Intervention: Concomitant therapy (CT)
Number of subjects: 68
Study 24357473 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein intake (<0.8 g/(kg · d))
Number of subjects: 1793
Study 24357473 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein intake (0.8-<1.0 g/(kg · d))
Number of subjects: 1793
Study 24357473 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intake (1.0-1.2 g/(kg · d))
Number of subjects: 1793
Study 23775182 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza infections in children
Number of subjects: 0
Study 23775182 — intervention group
Group type: COMPARATOR
Intervention: Influenza infections in adults
Number of subjects: 0
Study 20955336 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy
Number of subjects: 20
Study 20955336 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal exposure
Number of subjects: 20
Study 20955336 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 18173340 — intervention group
Group type: EXPERIMENTAL
Intervention: One-level arthroplasty with CHARITE artificial disc
Number of subjects: 0
Study 18173340 — intervention group
Group type: COMPARATOR
Intervention: One-level fusion with BAK and pedicle screws
Number of subjects: 0
Study 15985575 — intervention group
Group type: EXPERIMENTAL
Intervention: Open carpal tunnel release surgery
Number of subjects: 50
Study 15985575 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection
Number of subjects: 50
Study 12486283 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta1a (Avonex or Rebif)
Number of subjects: 0
Study 12486283 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (Copaxone)
Number of subjects: 0
Study 12486283 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose 6‐methylprednisolone
Number of subjects: 0
Study 12486283 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 0
Study 10785284 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate loading (CHO-loading) involving exhaustive one-legged cycling (73+/‐3% of maximal oxygen uptake for 130-160 min) followed by a low-CHO diet for 2-3 days and a high-CHO diet for the next 3 days.
Number of subjects: 16
Study 10785284 — intervention group
Group type: COMPARATOR
Intervention: Control leg (no CHO-loading).
Number of subjects: 16
Study 8679359 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 100
Study 8679359 — intervention group
Group type: EXPERIMENTAL
Intervention: dexamethasone 8 mg
Number of subjects: 100
Study 8679359 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron with dexamethasone (4 mg and 8 mg, respectively)
Number of subjects: 100
Study 8679359 — intervention group
Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 100
Study 1814445 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosed fluoridated dentifrice (0.085% F)
Number of subjects: 100
Study 1814445 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 100
Study 6834817 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal dilution technique
Number of subjects: 40
Study 30852440 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bubbles masking paradigm
Number of subjects: 0
Study 30852440 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-movements measured in conjunction with the bubbles paradigm
Number of subjects: 0
Study 30531690 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 589
Study 30531690 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 589
Study 26796524 — intervention group
Group type: EXPERIMENTAL
Intervention: Flick application before vaccination
Number of subjects: 0
Study 26796524 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual vaccination without flick application)
Number of subjects: 0
Study 24568227 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue protocol consisting of a repeated sprint ability (RSA) test (2 × 15‐m shuttle sprint interspersed with 20 seconds of passive recovery, repeated 6 times)
Number of subjects: 21
Study 24568227 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue protocol consisting of a repeated sprint ability (RSA) test
Number of subjects: 21
Study 21811829 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 ml warm water instillation (30 °C)
Number of subjects: 207
Study 21811829 — intervention group
Group type: COMPARATOR
Intervention: Conventional method without water instillation
Number of subjects: 207
Study 21344803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection (ITDI), administered once every week for a maximum of three sessions
Number of subjects: 21
Study 21344803 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 21
Study 17661541 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (Namenda)
Number of subjects: 4
Study 15643512 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (70 mg/m2), gemcitabine (1000 mg/m2), and cisplatin (35 mg/m2) on days 1 and 8 every 3 weeks (GCP)
Number of subjects: 85
Study 15643512 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m2 on days 1, 8, 15) and cisplatin (70 mg/m2 on day 2 every 4 weeks (GC)
Number of subjects: 85
Study 11773916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigar smoking
Number of subjects: 29
Study 11773916 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 9438780 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg of octreotide (OCT)
Number of subjects: 25
Study 9438780 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg of octreotide (OCT)
Number of subjects: 25
Study 9438780 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg of octreotide (OCT)
Number of subjects: 25
Study 7867444 — intervention group
Group type: EXPERIMENTAL
Intervention: HD‐Ara‐C (1.0 g/m2)
Number of subjects: 37
Study 7867444 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HD‐Ara‐C therapy)
Number of subjects: 37
Study 2671475 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt diet (220 mmol/day)
Number of subjects: 15
Study 2671475 — intervention group
Group type: COMPARATOR
Intervention: Low salt diet (20 mmol/day)
Number of subjects: 15
Study 801412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine HCl
Number of subjects: 30
Study 801412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31282394 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal decompression therapy (SDT) with core stabilization exercises (CSE)
Number of subjects: 31
Study 31282394 — intervention group
Group type: COMPARATOR
Intervention: Core stabilization exercises (CSE) alone
Number of subjects: 31
Study 31300012 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (6 mL/kg) in high P/F subgroup (> 150 mmHg)
Number of subjects: 836
Study 31300012 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (6 mL/kg) in low P/F subgroup (≤ 150 mmHg)
Number of subjects: 836
Study 31300012 — intervention group
Group type: COMPARATOR
Intervention: Traditional tidal volume ventilation in high P/F subgroup (> 150 mmHg)
Number of subjects: 836
Study 31300012 — intervention group
Group type: COMPARATOR
Intervention: Traditional tidal volume ventilation in low P/F subgroup (≤ 150 mmHg)
Number of subjects: 836
Study 29727545 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 120
Study 29727545 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-frequency transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 120
Study 29727545 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) + Mid-frequency TEAS
Number of subjects: 120
Study 29727545 — intervention group
Group type: COMPARATOR
Intervention: Control (TAM and TEAS)
Number of subjects: 120
Study 25906559 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with transperineal injection of 200 IU BTX-A
Number of subjects: 35
Study 25906559 — intervention group
Group type: COMPARATOR
Intervention: Transperineal injection of 200 IU BTX-A
Number of subjects: 35
Study 24143017 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse CAPs (200 µg/m(3))
Number of subjects: 35
Study 24143017 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine CAPs (250 µg/m(3))
Number of subjects: 35
Study 24143017 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (5.4 ng/m(3))
Number of subjects: 35
Study 24143017 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 35
Study 24143017 — intervention group
Group type: COMPARATOR
Intervention: Medical air
Number of subjects: 35
Study 21148044 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet of alendronate/vitamin D(3)
Number of subjects: 0
Study 21148044 — intervention group
Group type: COMPARATOR
Intervention: ALN 70 mg
Number of subjects: 0
Study 21148044 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D(3) alone
Number of subjects: 0
Study 19664769 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (50 mg)
Number of subjects: 160
Study 19664769 — intervention group
Group type: EXPERIMENTAL
Intervention: Valethamate bromide (16 mg)
Number of subjects: 160
Study 19664769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 160
Study 17175376 — intervention group
Group type: EXPERIMENTAL
Intervention: CA repeat polymorphism in the EGFR gene
Number of subjects: 0
Study 15135191 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube (LT)
Number of subjects: 60
Study 15135191 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (ETI)
Number of subjects: 60
Study 15135191 — intervention group
Group type: COMPARATOR
Intervention: Bag-valve mask (BVM)
Number of subjects: 60
Study 11789320 — intervention group
Group type: EXPERIMENTAL
Intervention: Huang Qi Gu Jing Yin (HQGJY)
Number of subjects: 30
Study 11789320 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study 9417487 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral selenium supplementation (week 1: twice 500 micrograms daily, week 2: once 500 micrograms, week 3: three times 100 micrograms sodium selenite)
Number of subjects: 24
Study 9417487 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral selenium supplementation
Number of subjects: 24
Study 9417487 — intervention group
Group type: COMPARATOR
Intervention: Control group (no selenium supplementation)
Number of subjects: 24
Study 7679737 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (12.5 mg)
Number of subjects: 6
Study 7679737 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg)
Number of subjects: 6
Study 7679737 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (0.75, 1.5 and 3 mg)
Number of subjects: 6
Study 7679737 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (15, 30 and 60 mg)
Number of subjects: 6
Study 7679737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2867610 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 51
Study 2867610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 2867610 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 51
Study 30833436 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (150 mg/m2) administered intravenously over 90 min on day 1, and S-1 (80 mg/m2) given orally in two divided doses from days 1 to 14 of a 21 day cycle.
Number of subjects: 19
Study 30833436 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus S-1
Number of subjects: 19
Study 30954164 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous coupler
Number of subjects: 124
Study 30954164 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn anastomosis
Number of subjects: 124
Study 26549803 — intervention group
Group type: EXPERIMENTAL
Intervention: Perforated membranes (PM)
Number of subjects: 30
Study 26549803 — intervention group
Group type: EXPERIMENTAL
Intervention: Open flap debridement (OFD)
Number of subjects: 30
Study 26549803 — intervention group
Group type: COMPARATOR
Intervention: Occlusive membrane (OM)
Number of subjects: 30
Study 23979497 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/STI intervention
Number of subjects: 848
Study 23979497 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 848
Study 22326480 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive, tailored multimodal exercise program in addition to the standard osteoporosis exercise program
Number of subjects: 41
Study 22326480 — intervention group
Group type: COMPARATOR
Intervention: Standard osteoporosis exercise program alone
Number of subjects: 41
Study 21047625 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-search paradigm testing with an agent demonstrating a rattling object
Number of subjects: 0
Study 21047625 — intervention group
Group type: EXPERIMENTAL
Intervention: Inference and memory-based prompts in the non-search paradigm
Number of subjects: 0
Study 21047625 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional results from Experiment 3
Number of subjects: 0
Study 17984395 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs) including olanzapine, quetiapine fumarate, risperidone
Number of subjects: 421
Study 17984395 — intervention group
Group type: COMPARATOR
Intervention: Placebo (representing a 'watchful waiting' treatment strategy)
Number of subjects: 421
Study 15759023 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 106
Study 15759023 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive drug therapy
Number of subjects: 106
Study 14638565 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly patient self-management with phenprocoumon
Number of subjects: 341
Study 14638565 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly management at an anticoagulation clinic with phenprocoumon
Number of subjects: 341
Study 14638565 — intervention group
Group type: COMPARATOR
Intervention: Existing routine care group (untrained in self-management)
Number of subjects: 341
Study 14638565 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly management with acenocoumarol
Number of subjects: 341
Study 14638565 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care group of trained patients
Number of subjects: 341
Study 10823572 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory vaccination program for HCWs (intramuscular half dose from 1990 to 1995, intradermal from 1983 to 1989)
Number of subjects: 0
Study 10823572 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory vaccination program for high-risk workers
Number of subjects: 0
Study 8654109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lensmeter 701 (LOM)
Number of subjects: 410
Study 8654109 — intervention group
Group type: COMPARATOR
Intervention: Lens Opacities Classification System II (LOCS II)
Number of subjects: 410
Study 1626674 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine at a dose of 0.2 mg.kg‐1
Number of subjects: 100
Study 1626674 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 100
Study 6093979 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose CAV (HD-CAV) - cyclophosphamide 1200 mg/m2, doxorubicin 70 mg/m2, vincristine 1 mg/m2 IV on days 1 and 21
Number of subjects: 293
Study 6093979 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose CAV + VP-16 (CAV-VP) - cyclophosphamide 1000 mg/m2, doxorubicin 40 mg/m2, vincristine 1 mg/m2 IV on days 1 and 21 with VP-16 100 mg/m2 on days 1-3 and 21-23
Number of subjects: 293
Study 3742319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 300 mg PO the night prior to surgery and 300 mg IV 30 minutes prior to anaesthesia induction (Part 1)
Number of subjects: 62
Study 3742319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine continued for 24 hours into the postoperative period (Part 2)
Number of subjects: 62
Study 3742319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Part 1)
Number of subjects: 62
Study 3742319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Part 2)
Number of subjects: 62
Study 29550085 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg once daily plus a P2Y12 inhibitor
Number of subjects: 2124
Study 29550085 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus dual antiplatelet therapy (DAPT)
Number of subjects: 2124
Study 29550085 — intervention group
Group type: COMPARATOR
Intervention: Dose-adjusted warfarin plus DAPT
Number of subjects: 2124
Study 28264695 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and physical activity intervention
Number of subjects: 17
Study 28264695 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection methods
Number of subjects: 17
Study 28264695 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for future trials
Number of subjects: 17
Study 26409410 — intervention group
Group type: COMPARATOR
Intervention: High-frequency rTMS (90% of resting motor threshold, 10 Hz, 1,000 pulses) applied over the lower leg primary motor cortex (M1-LL) for five sessions in a week.
Number of subjects: 17
Study 26409410 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control condition) with a two-week wash out period.
Number of subjects: 17
Study 24171782 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized acupuncture point prescriptions, 20 sessions over four weeks.
Number of subjects: 249